AMDL Management Team in China for Key Business Initiatives
April 26 2007 - 9:56AM
PR Newswire (US)
TUSTIN, Calif., April 26 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), an international biopharma company with operations in
China through its wholly owned subsidiary, Jade Pharmaceutical Inc.
(JPI), today announced that its second quarter initiatives will
include a trip by the Company's senior management to China to
initiate business strategies and opportunities that are now
available due to the recently completed financing. The Company
received subscriptions for $3.8 million in gross proceeds. "We
intend to implement broader and stronger relationships with new
China- based pharmaceutical distributors in order to significantly
expand the depth and breadth of JPI product distribution channels
within China," said Gary Dreher, CEO. "AMDL will also finalize new
industry partnerships with other China based pharmaceutical
companies to commence clinical trials of our Combination Immunogene
Therapy (CIT) cancer technology." AMDL's CIT employs an innovative
approach whereby two genes are inserted into tumor cells to both
build the immune system and destroy cancer cells. "During our trip,
we will review JPI's progress in obtaining regulatory approval of
DR-70(R) by China's State Food and Drug Administration," Mr. Dreher
said. "Our management team will also work to develop a new retail
pharmaceutical sales opportunity that will significantly expand
JPI's current sales." "The recent announcement of the completion of
additional financing gives AMDL and JPI greater financial strength
to pursue our expansion strategies. We anticipate that 2007 will be
a strong growth year for the Company," said Mr. Dreher. About AMDL
AMDL, Inc., headquartered in Tustin, California, with operations in
Shenzhen, Jaingxi and Jilin China through its wholly owned
subsidiary Jade Pharmaceutical Inc., is an international biopharma
company. AMDL together with Jade engages in the development,
manufacture and marketing of proprietary pharmaceutical and testing
products. More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024